Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





End-to-End Diagnostic Platform Could Be Game Changer for En-Masse, Rapid and Precise COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 27 Oct 2021

A new diagnostic platform could be a game-changing, end-to-end solution for en-masse, rapid and precise diagnosis of COVID-19 and other viruses at the point-of-care (POC). More...

Dotz Nano Ltd.’s (Kefar-Sava, Israel) Mega-Diagnostic Platform is an all-in-one solution that consists of proprietary DOTZ Test Kits, an integrated diagnostic system, and a results-management system. The Dotz Mega-Diagnostic Platform is based on RT-LAMP (Loop-Mediated Isothermal Amplification) technology with >95% true positive rate for viral loads of 1250 copies per mL; and 100% specificity.

Dotz’s platform provides an integrated and cost-efficient solution for SARS-CoV-2 testing that has the capacity to simultaneously test up to 96 samples per device in approximately 30 minutes. The test produces a visually-detectable change in the color of samples, ensuring a simple and rapid analysis procedure. The platform can use both saliva and nasopharyngeal samples for a more comfortable testing experience, particularly for children.

The Dotz Mega-Diagnostic Platform can be used in organizations or locations that are required to perform large numbers of tests in a short time, such as airports, universities, factories, workplaces, border crossings, and more. It requires minimal operator training, thereby significantly lowering overhead costs such as medical personnel and laboratory equipment. Dotz’s diagnostic solution has been granted CE Mark Authorization from the European Union, and it has also applied for Emergency Use Authorization from the FDA. Dotz will showcase its Mega-Diagnostic Platform for the first time at the MEDICA 2021 Trade Fair in Dusseldorf, Germany, November 15-18th.

“From the outbreak of the pandemic up to this point, en-masse and accurate detection of COVID-19 relied on complex and slow methods that must be performed in well-equipped laboratories by trained personnel,” said Gideon Shmuel, CEO of Dotz. “Our integrated, simple-to-use solution brings rapid and highly-accurate testing capabilities to the field, supporting a resumption of normal economic activity while keeping those transiting highly-trafficked public spaces healthy and safe.”

Related Links:
Dotz Nano Ltd. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.